3430p -22.0 -0.6%
Last Trade - 26/02/21
| Market Cap | £3.71bn |
| Enterprise Value | £3.91bn |
| Revenue | £566.4m |
| Position in Universe | 213th / 1807 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 203.5 | 247.6 | 359.3 | 407.1 | 481.8 | 515.1 | 582.6 | 631.3 | +20.4% | ||
| +12.6 | +4.4 | +153.7 | +24.2 | -7.4 | -2.1 | +73.7 | +7.46 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | May 13, 1997 |
| Public Since | September 21, 2000 |
| No. of Shareholders: | n/a |
| No. of Employees: | 1,808 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE All Share , FTSE All-share - Health Care Price Return Gbp End Of Day, FTSE All-share - Pharmaceuticals & Biotechnology Price Return Gbp End Of Day, FTSE 350 , FTSE 350 Lower Yield , FTSE 250 , FTSE 350 Pharmaceuticals & Biotechnology , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 108,152,833 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Lostock Gralam, NORTHWICH, CW9 7UA, United Kingdom |
| Web | http://www.dechra.com/ |
| Phone | +44 1606 814730 |
| Contact | Ian Page (Chief Executive Officer, Executive Director) |
| Auditors | PricewaterhouseCoopers LLP |
As of 26/02/21, shares in Dechra Pharmaceuticals are trading at 3430p, giving the company a market capitalisation of £3.71bn. This share price information is delayed by 15 minutes.
Shares in Dechra Pharmaceuticals are currently trading at 3430p and the price has moved by 28.46% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Dechra Pharmaceuticals price has moved by 24.56% over the past year.
Of the analysts with advisory recommendations for Dechra Pharmaceuticals, there are there are currently 3 "buy" , 4 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Dechra Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Dechra Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:
The Dechra Pharmaceuticals dividend yield is 1.02% based on the trailing twelve month period.
Last year, Dechra Pharmaceuticals paid a total dividend of 0.35, and it currently has a trailing dividend yield of 1.02%. Looking ahead, shares in Dechra Pharmaceuticals are due to go ex-dividend on 2021-03-04 and the next dividend pay date is 2021-04-07.
Dechra Pharmaceuticals are due to go ex-dividend on 2021-03-04 and the next dividend pay date is 2021-04-07. The historic dividend yield on Dechra Pharmaceuticals shares is currently 1.02%.
To buy shares in Dechra Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Dechra Pharmaceuticals are currently trading at 3430p, giving the company a market capitalisation of £3.71bn.
Here are the trading details for Dechra Pharmaceuticals:
Based on an overall assessment of its quality, value and momentum, Dechra Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Dechra Pharmaceuticals are currently priced at 3430p. At that level they are trading at 7.35% discount to the analyst consensus target price of 3,702.10.
Analysts covering Dechra Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of 1.01725 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dechra Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -5.42%. At the current price of 3430p, shares in Dechra Pharmaceuticals are trading at 5.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dechra Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 53.62. The shares are currently trading at 3430p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dechra Pharmaceuticals's management team is headed by:
Here are the top five shareholders of Dechra Pharmaceuticals based on the size of their shareholding:
